文献速递泌尿生殖与妇科肿瘤放疗

早期子宫内膜癌短程辅助阴道穹隆近距离放疗与标准治疗的经济效益比较:SAVE试验

Financial Improvements From Short Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared With Standard of Care, "SAVE" Trial.
PubMed 文献 · Pract Radiat Oncol · 2024-09-13

SAVE试验为多中心前瞻性随机试验,比较标准治疗(SoC)3–5次阴道穹隆近距离放疗(VCB)与2次方案的财务成本终点。共分析108例患者,2次方案较SoC显著降低技术费用和总费用,并减少5次治疗患者的出行距离和交通费用。

要点

  • 2次VCB较SoC显著降低技术费用($24,696 vs $35,734,p≤.01)和总费用($32,228 vs $44,892,p<.01)。
  • 5次治疗较2次治疗出行距离更长(中位462 vs 137英里,p<.01),交通费用更高(中位$59.3 vs $18.0,p≤.01)。
  • SoC与试验组未调整的原始专业费用无显著差异($9159 vs $7532,p=.19)。

核心结论

  • 2次VCB方案减少每例治疗次数,较更长疗程降低交通费用,并较SoC降低调整后的医疗支出。

研究设计与样本

  • 多中心前瞻性随机试验,比较标准治疗(SoC)3–5次(由医生决定)与2次VCB方案,报告次要成本终点,共分析108例患者。

主要发现

  • SoC组54例中3次、4次、5次VCB分别为27例(50%)、11例(20%)、16例(30%)。
  • SoC组与试验组每例中位总出行距离为213 vs 137英里(p=.12),中位交通费用为$36.3 vs $18.0(p=.11)。
  • 5次治疗较2次治疗中位出行距离更长(462 vs 137英里,p<.01),中位交通费用更高($59.3 vs $18.0,p≤.01)。
  • SoC组与试验组未调整的原始专业费用无显著差异($9159 vs $7532,p=.19)。
  • SoC组技术费用显著更高($35,734 vs $24,696,p≤.01),总费用也显著更高($44,892 vs $32,228,p<.01);Medicare调整后的技术费用和总费用在SoC组更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Early-stage endometrial cancer is often treated with hysterectomy followed by adjuvant vaginal cuff brachytherapy (VCB). Financial toxicity from cancer treatment can impact treatment completion. The Short Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared to Standard of Care trial is a multicenter, prospective randomized trial of standard of care (SoC) VCB doses delivered in 3 to 5 fractions per the physician's discretion compared with a 2-fraction course. We report on secondary cost endpoints, quantifying the financial impacts of shorter treatment courses on institutions and participating patients. METHODS AND MATERIALS: Technical (TechCs), professional, and total charges (TotCs) were collected prospectively and are reported as raw and Medicare-adjusted charges per patient. Distance to the treatment center and the median income for each patient's zip code were estimated. The Mann-Whitney U statistic, t test, and X2 test were used to compare characteristics between the 2 groups. RESULTS: One hundred eight patients were analyzed. SoC VCB was delivered in 3, 4, and 5 fractions for 27 of 54 patients (50%), 11 of 54 (20%), and 16 of 54 (30%), respectively. The median total distance traveled per patient for SoC versus experimental arms was 213 versus 137 miles (p = .12), and the median cost of commute for patients was $36.3 versus $18.0 (p = .11). Compared with 2-fraction treatment, 5-fraction treatment resulted in longer travel distances (median, 462 vs 137 miles; p < .01) and increased travel costs (median, $59.3 vs $18.0; p ≤ .01). Unadjusted raw professional charges in USD per patient did not differ between SoC versus experimental arms ($9159 vs $7532; p = .19). TechCs were significantly higher in the SoC arm ($35,734 vs $24,696; p ≤ .01), as were TotCs ($44,892 vs $32,228; p < .01;). Medicare-adjusted TechCs and TotCs were higher for the SoC arm. CONCLUSIONS: Two-fraction VCB resulted in fewer treatments per patient, reduced cost of travel compared with longer courses, and an adjusted reduction in health care expenditures compared with SoC.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. DeCesaris C, Wilson T, Kim J, et al. Financial Improvements From Short Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared With Standard of Care, "SAVE" Trial. Pract Radiat Oncol. 2024. PMID: 39269405. doi:10.1016/j.prro.2024.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。